Trieu Mai-Chi, Reynaldi Arnold, Lee Wen Shi, Tan Hyon-Xhi, Kelly Andrew, Esterbauer Robyn, Cox Rebecca J, Audsley Jennifer, Sasadeusz Joseph, Khoury David S, Davenport Miles P, Cromer Deborah, Wheatley Adam K, Kent Stephen J, Juno Jennifer A
Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
NPJ Vaccines. 2025 Apr 18;10(1):74. doi: 10.1038/s41541-025-01129-6.
The ongoing rollout of SARS-CoV-2 vaccines lags behind rapid viral evolution. Updated vaccine immunogens elicit neutralising antibodies against the component strain. However, protection against future SARS-CoV-2 variants is unclear. Here, we sought to understand factors underpinning serological breadth following bivalent BA.1 vaccination. Booster vaccination of 33 individuals elicited robust and durable antibody responses against component vaccine antigens and elevated frequencies of spike-specific CD4 and CD8 T cells. Immunisation predominantly drove recall of cross-reactive memory B cells which also recognised XBB.1.5 spike, with significantly enhanced neutralisation titres against XBB virus seen within 91% of participants. Multivariate regression indicated that both baseline neutralising titres and spike-specific CD4 T cell frequencies were strong predictors of ancestral, BA.1 and XBB neutralisation post-immunisation. These data highlight that updated SARS-CoV-2 vaccines recall cross-reactive memory that maintains recognition of antigenically evolved viral variants and suggests T cell help and prior antibody titres underpin robust vaccine-induced neutralising activity.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗的持续推广落后于病毒的快速进化。更新后的疫苗免疫原可引发针对组成毒株的中和抗体。然而,针对未来SARS-CoV-2变体的保护作用尚不清楚。在此,我们试图了解二价BA.1疫苗接种后血清学广度的影响因素。对33名个体进行加强免疫接种后,引发了针对组成疫苗抗原的强大而持久的抗体反应,并提高了刺突特异性CD4和CD8 T细胞的频率。免疫接种主要促使对交叉反应性记忆B细胞的回忆,这些细胞也能识别XBB.1.5刺突,91%的参与者体内针对XBB病毒的中和滴度显著提高。多变量回归表明,基线中和滴度和刺突特异性CD4 T细胞频率都是免疫接种后对原始毒株、BA.1和XBB中和作用的有力预测指标。这些数据突出表明,更新后的SARS-CoV-2疫苗能唤起交叉反应性记忆,维持对抗原进化的病毒变体的识别,并表明T细胞辅助和先前的抗体滴度是强大的疫苗诱导中和活性的基础。